Literature DB >> 15197575

[Clinical and genetic results with reference to corneal alterations in Lowe-syndrome].

G Rudolph1, P Kalpadakis, W Röschinger, C Haritoglou, S Kammerer, K-P Boergen, A Kampik.   

Abstract

BACKGROUND: The Lowe oculo-cerebro-renal syndrome (OCRL1) is a rare X-linked disease which causes impairment of visual acuity. The situation may be further complicated by corneal alterations. PATIENTS AND METHODS: In total seven patients from different families were clinically examined by slit-lamp examination, funduscopy, measurement of the intraocular pressure and ultrasound sonography. Molecular genetic analysis was performed in six patients by sequencing large PCR amplicons with a DNA sequencer and the ABI PRISM Sequence navigator software. RESULT: All affected boys were aphakic. Due to high intraocular pressure, iridectomy, goniotomy, cyclo-cryo treatment or trabeculectomy were performed. All patients showed opacity or pannus-like alterations of the cornea. Molecular genetic analysis revealed four novel and two known mutations.
CONCLUSION: Reduced visual acuity was partly explained by morphological changes due to the underlying genetic defect and the development of cataract and glaucoma. Opacity of the cornea as well as alterations of the cornea seem to be a major problem in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197575     DOI: 10.1007/s00347-003-0941-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  17 in total

1.  The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase.

Authors:  O Attree; I M Olivos; I Okabe; L C Bailey; D L Nelson; R A Lewis; R R McInnes; R L Nussbaum
Journal:  Nature       Date:  1992-07-16       Impact factor: 49.962

2.  Ocular pathology of Lowe's syndrome in a female infant.

Authors:  B L Johnson; D A Hiles
Journal:  J Pediatr Ophthalmol       Date:  1976 Jul-Aug

3.  Opacities of the lens indicating carrier status in the oculo-cerebro-renal (Lowe) syndrome.

Authors:  J W Delleman; E M Bleeker-Wagemakers; A W van Veelen
Journal:  J Pediatr Ophthalmol       Date:  1977 Jul-Aug

4.  Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation; a clinical entity.

Authors:  C U LOWE; M TERREY; E A MacLACHLAN
Journal:  AMA Am J Dis Child       Date:  1952-02

5.  Physical mapping and genomic structure of the Lowe syndrome gene OCRL1.

Authors:  R L Nussbaum; B M Orrison; P A Jänne; L Charnas; A C Chinault
Journal:  Hum Genet       Date:  1997-02       Impact factor: 4.132

6.  Lowe syndrome: identification of the carrier state.

Authors:  N Brown; R J Gardner
Journal:  Birth Defects Orig Artic Ser       Date:  1976

7.  Mapping the Lowe oculocerebrorenal syndrome to Xq24-q26 by use of restriction fragment length polymorphisms.

Authors:  D N Silver; R A Lewis; R L Nussbaum
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

8.  Characterization of a germline mosaicism in families with Lowe syndrome, and identification of seven novel mutations in the OCRL1 gene.

Authors:  V Satre; N Monnier; F Berthoin; C Ayuso; A Joannard; P S Jouk; I Lopez-Pajares; A Megabarne; H J Philippe; H Plauchu; M L Torres; J Lunardi
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

9.  Unusual renal features of Lowe syndrome in a mildly affected boy.

Authors:  A Gropman; S Levin; L Yao; T Lin; S Suchy; S Sabnis; D Hadley; R Nussbaum
Journal:  Am J Med Genet       Date:  2000-12-18

10.  Pathogenesis of cataracts in patients with Lowe's syndrome.

Authors:  R C Tripathi; G W Cibis; B J Tripathi
Journal:  Ophthalmology       Date:  1986-08       Impact factor: 12.079

View more
  1 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.